Fig. 2
From: Management of a patient with common variable immunodeficiency and hepatopathy
a: Time course of aspartate aminotransferase (GOT/AST) levels. Start of anti-viral therapy (Ribavirin) with 200 mg 1-0-1 on 02/09/2021, increase of dosage to 400 mg 1-0-1 on 03/11/2021. Negative PCR detection for HEV-RNA on 06/07/2021. b: Time course of alanine aminotransferase (GPT/ALT) levels. Start of anti-viral therapy (Ribavirin) with 200 mg 1-0-1 on 02/09/2021, increase of dosage to 400 mg 1-0-1 on 03/11/2021. Negative PCR detection for HEV-RNA on 06/07/2021